BLUE News and Press, bluebird bio Inc. From 09/28/20

bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the Jefferies Cell Therapy Virtual Summit, Tuesday, October 6, at 2:00 p.m. ET. To access the live webcast of bluebird bio’s presentation, please visit the “Events...

ZYNTEGLO has received conditional approval in Europe for those with transfusion-dependent beta-thalassemia. Goal is to expand approval to include pediatric patients and those with β0/β0 genotype. A BLA filing of ZYNTEGLO for the treatment of patients with transfusion-dep...

Bluebird bio's (BLUE) LentiGlobin, an investigational gene therapy (bb1111) for the treatment of sickle cell disease ((SCD)) was granted eligibility to the Priority Medicines ((PRIME)) program by the EMA.PRIME, akin to Breakthrough Therapy status in the U.S., provides for more intensive ...

EMA’s PRIME program designed to optimize development and expedite evaluation of innovative medicines for patients with high unmet need bluebird bio, Inc. (Nasdaq: BLUE) announced today that its investigational treatment for sickle cell disease (SCD), LentiGlob...

A novel approach to multiple myeloma treatment developed by Bristol-Myers Squibb (NYSE: BMY) and bluebird bio (NASDAQ: BLUE) took an important step toward commercialization on Tuesday when the Food and Drug Administration announced that it had accepted their application for ...

Under Priority Review status, the FDA accepts Bristol Myers Squibb's (BMY) marketing application seeking approval of B-cell maturation antigen ((BCMA))-directed CAR T therapy idecabtagene vicleucel (ide-cel; bb2121) for the treatment of adult multiple myeloma patients who have received at lea...

FDA set a target action date of March 27, 2021 Ide-cel is the first CAR T cell therapy accepted for regulatory review for multiple myeloma Bristol Myers Squibb (NYSE: BMY) and bluebird bio, Inc . (Nasdaq: BLUE) today announced that the U.S. Fo...

In 2019, nearly 1,100 persons attended the annual Precious Metals Summit at the Beaver Creek Resort in Colorado. Over 180 companies and 262 buy-side firms were also represented. This year the conference will be virtual, and indications are attendance and participation may surpass last yearȁ...

bluebird bio (NASDAQ: BLUE) is a biotech company that specializes in gene editing, a technology that allows scientists to modify the genetic material of living organisms. Gene editing has the potential to produce life-changing therapies for conditions for which there are few (if any) treatme...

The Contingent Value Right (CVR) (NYSE: BMY.RT ) associated with Bristol Myers Squibb's ( BMY -2.2% ) $74B takeover of Celgene is down  ~24%  today in apparent reaction to management comments at a Citigroup conference revealing that the manufacturing plant for CAR T therapi...